131 related articles for article (PubMed ID: 17661170)
1. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data.
Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
Breast Cancer Res Treat; 2008 Jun; 109(3):559-66. PubMed ID: 17661170
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
4. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.
Purmonen TT; Pänkäläinen E; Turunen JH; Asseburg C; Martikainen JA
Acta Oncol; 2011 Apr; 50(3):344-52. PubMed ID: 21299447
[TBL] [Abstract][Full Text] [Related]
5. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer].
Fagnani F; Colin X; Arveux P; Coudert B; Misset JL
Bull Cancer; 2007 Jul; 94(7):711-20. PubMed ID: 17723955
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
Neyt M; Huybrechts M; Hulstaert F; Vrijens F; Ramaekers D
Health Policy; 2008 Aug; 87(2):146-59. PubMed ID: 18164510
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
10. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
11. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.
Chen W; Jiang Z; Shao Z; Sun Q; Shen K
Value Health; 2009; 12 Suppl 3():S82-4. PubMed ID: 20586989
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis.
Norum J; Olsen JA; Wist EA; Lønning PE
Acta Oncol; 2007; 46(2):153-64. PubMed ID: 17453363
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
Blank PR; Schwenkglenks M; Moch H; Szucs TD
Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.
Perez-Ellis C; Goncalves A; Jacquemier J; Marty M; Girre V; Roché H; Brain E; Moatti JP; Viens P; Le Corroller-Soriano AG
Am J Clin Oncol; 2009 Oct; 32(5):492-8. PubMed ID: 19487912
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.
Van Vlaenderen I; Canon JL; Cocquyt V; Jerusalem G; Machiels JP; Neven P; Nechelput M; Delabaye I; Gyldmark M; Annemans L
Acta Clin Belg; 2009; 64(2):100-12. PubMed ID: 19432022
[TBL] [Abstract][Full Text] [Related]
19. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial.
Skedgel C; Rayson D; Younis T
Value Health; 2009; 12(5):641-8. PubMed ID: 19490562
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial.
Dedes KJ; Szucs TD; Imesch P; Fedier A; Fehr MK; Fink D
Ann Oncol; 2007 Sep; 18(9):1493-9. PubMed ID: 17761705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]